The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 29, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

September 30, 2026

Conditions
Hematopoietic Recovery
Interventions
DRUG

Coenzyme I for Injection

Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.

Trial Locations (1)

230036

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV